贝伐珠单抗对比阿柏西普对中央视网膜静脉阻塞所致黄斑水肿患者视力的影响:SCORE2随机临床试验
SCORE2随机非劣效性试验在美国66个中心纳入362例中央或半侧视网膜静脉阻塞所致黄斑水肿患者,按1:1随机接受贝伐珠单抗1.25 mg或阿柏西普2.0 mg玻璃体腔注射,每4周一次至第6个月。第6个月贝伐珠单抗组视力字母评分平均增加18.6,阿柏西普组平均增加18.9,组间差异-0.14(97.5% CI -3.07至∞;非劣效性P=0.001),达到非劣效标准。
要点
- 贝伐珠单抗1.25 mg每4周注射至第6个月,在视力改善方面非劣效于阿柏西普2.0 mg。
- 第6个月贝伐珠单抗组视力字母评分平均增加18.6,阿柏西普组平均增加18.9。
- 贝伐珠单抗组报告眼内炎1例(培养阴性)、眼压高于基线10 mm Hg以上9例。
核心结论
- 在中央或半侧视网膜静脉阻塞所致黄斑水肿患者中,玻璃体腔注射贝伐珠单抗在治疗6个月后视力方面非劣效于阿柏西普。
研究设计与样本
- SCORE2随机非劣效性临床试验在美国66个私人诊所或学术中心开展,纳入362例中央或半侧视网膜静脉阻塞所致黄斑水肿患者,按1:1随机接受阿柏西普或贝伐珠单抗。
- 首例受试者于2014年9月17日随机化,最后一例第6个月随访于2016年5月6日完成,分析纳入截至2016年12月30日可获得的数据。
主要发现
- 共362例随机受试者(平均[SD]年龄69[12]岁;女性157例[43.4%];基线平均[SD]视力字母评分50.3[15.2],约相当于Snellen视力20/100),348例(96.1%)完成第6个月随访。
- 第6个月贝伐珠单抗组平均视力字母评分为69.3(较基线平均增加18.6),阿柏西普组为69.3(较基线平均增加18.9),基于模型估计的组间差异为-0.14(97.5% CI -3.07至∞;非劣效性P=0.001),达到非劣效标准。
- 阿柏西普组眼部不良事件包括4例眼压高于基线10 mm Hg以上;贝伐珠单抗组眼部不良事件包括1例眼内炎(培养阴性)、9例眼压高于基线10 mm Hg以上、2例眼压高于35 mm Hg、1例闭角型青光眼(未归因于研究药物或操作)。
关键数值与推荐
- 主要结局为随机化访视至第6个月随访访视的最佳矫正电子早期糖尿病视网膜病变治疗研究视力字母评分平均变化(评分范围0-100,评分越高视力越好)。
- 非劣效界值为5个字母,非劣效性统计检验基于单侧97.5%置信区间。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Studies have established the efficacy and safety of aflibercept for the treatment of macular edema due to central retinal vein occlusion. Bevacizumab is used off-label to treat this condition despite the absence of supporting data. OBJECTIVE: To investigate whether bevacizumab is noninferior to aflibercept for the treatment of macular edema secondary to central retinal or hemiretinal vein occlusion. DESIGN, SETTING, AND PARTICIPANTS: The SCORE2 randomized noninferiority clinical trial was conducted at 66 private practice or academic centers in the United States, and included 362 patients with macular edema due to central retinal or hemiretinal vein occlusion who were randomized 1:1 to receive aflibercept or bevacizumab. The first participant was randomized on September 17, 2014, and the last month 6 visit occurred on May 6, 2016. Analyses included data available as of December 30, 2016. INTERVENTIONS: Eyes were randomized to receive intravitreal injection of bevacizumab (1.25 mg; n = 182) or aflibercept (2.0 mg; n = 180) every 4 weeks through month 6. MAIN OUTCOMES AND MEASURES: The primary outcome was mean change in visual acuity (VA) letter score (VALS) from the randomization visit to the 6-month follow-up visit, based on the best-corrected electronic Early Treatment Diabetic Retinopathy Study VALS (scores range from 0-100; higher scores indicate better VA). The noninferiority margin was 5 letters, and statistical testing for noninferiority was based on a 1-sided 97.5% confidence interval. RESULTS: Among 362 randomized participants (mean [SD] age, 69 [12] years; 157 [43.4%] women; mean [SD] VALS at baseline, 50.3 [15.2] [approximate Snellen VA 20/100]), 348 (96.1%) completed the month 6 follow-up visit. At month 6, the mean VALS was 69.3 (a mean increase from baseline of 18.6) in the bevacizumab group and 69.3 (a mean increase from baseline of 18.9) in the aflibercept group (model-based estimate of between-group difference, -0.14; 97.5% CI, -3.07 to ∞; P = .001 for noninferiority), meeting criteria for noninferiority. Ocular adverse events in the aflibercept group included 4 participants with intraocular pressure (IOP) more than 10 mm Hg greater than baseline; ocular adverse events in the bevacizumab group included 1 participant with endophthalmitis (culture negative), 9 with IOP more than 10 mm Hg greater than baseline, 2 with IOP higher than 35 mm Hg, and 1 with angle-closure glaucoma not attributed to the study drug or procedure. CONCLUSIONS AND RELEVANCE: Among patients with macular edema due to central retinal or hemiretinal vein occlusion, intravitreal bevacizumab was noninferior to aflibercept with respect to visual acuity after 6 months of treatment.
引用
- Scott IU, VanVeldhuisen PC, Ip MS, et al. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. JAMA. 2017. PMID: 28492910. doi:10.1001/jama.2017.4568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。